{ "api_version": "1", "request": { "url": "https://clinicaltrialsfind.com/api/v1/search.json?intervention=Clinical+Adjudication&page=2", "query": { "intervention": "Clinical Adjudication", "page": 2 }, "page_size": 10 }, "pagination": { "page": 2, "page_size": 10, "total_count": 10, "total_pages": 1, "next_page_url": null, "previous_page_url": "https://clinicaltrialsfind.com/api/v1/search.json?intervention=Clinical+Adjudication&page=1&page_size=10" }, "source": "remote", "last_synced_at": "2026-09-26T11:54:21.516Z", "attribution": "Data derived from public ClinicalTrials.gov records. The official record at https://clinicaltrials.gov/ remains the source of truth for current availability, contacts, and full study details.", "notes": [ "This endpoint exposes only public summary fields — no participant contact emails, phone numbers, or scraped investigator contact details.", "For contact information and full protocol detail, follow each trial's `official_url` to the ClinicalTrials.gov record.", "This API is a navigational aid. It does not provide medical advice, eligibility determinations, or compensation guarantees." ], "trials": [ { "nct_id": "NCT03758157", "title": "Clinical Accuracy of the welloStationX", "overall_status": "COMPLETED", "study_type": "OBSERVATIONAL", "phases": [], "conditions": [ "Fever" ], "interventions": [ { "name": "welloStationX", "type": "DIAGNOSTIC_TEST" }, { "name": "SureTemp", "type": "DIAGNOSTIC_TEST" } ], "intervention_types": [ "DIAGNOSTIC_TEST" ], "sponsor": "Wello Inc.", "sponsor_class": "INDUSTRY", "healthy_volunteers": true, "eligibility": { "minimum_age": "5 Years", "maximum_age": null, "sex": "ALL", "summary": "5 Years and older" }, "enrollment_count": 110, "start_date": "2018-10-15", "completion_date": "2018-11-15", "has_results": true, "last_update_posted_date": "2021-07-07", "last_synced_at": "2026-09-26T11:54:21.516Z", "location_count": 1, "location_summary": "Dallas, Texas", "locations": [ { "city": "Dallas", "state": "Texas" } ], "official_url": "https://clinicaltrials.gov/study/NCT03758157" }, { "nct_id": "NCT05371483", "title": "Cardiovascular and Cognitive Implications of Central Disorders of Hypersomnolence and Their Treatments", "overall_status": "ENROLLING_BY_INVITATION", "study_type": "OBSERVATIONAL", "phases": [], "conditions": [ "Narcolepsy", "Idiopathic Hypersomnia" ], "interventions": [ { "name": "24-hour Ambulatory Blood Pressure Monitoring", "type": "DIAGNOSTIC_TEST" }, { "name": "Oculo-Cognitive Addition Test (OCAT)", "type": "DIAGNOSTIC_TEST" } ], "intervention_types": [ "DIAGNOSTIC_TEST" ], "sponsor": "Mayo Clinic", "sponsor_class": "OTHER", "healthy_volunteers": false, "eligibility": { "minimum_age": "18 Years", "maximum_age": "75 Years", "sex": "ALL", "summary": "18 Years to 75 Years" }, "enrollment_count": 100, "start_date": "2022-05-18", "completion_date": "2028-07", "has_results": false, "last_update_posted_date": "2026-06-09", "last_synced_at": "2026-09-26T11:54:21.516Z", "location_count": 1, "location_summary": "Scottsdale, Arizona", "locations": [ { "city": "Scottsdale", "state": "Arizona" } ], "official_url": "https://clinicaltrials.gov/study/NCT05371483" }, { "nct_id": "NCT03013998", "title": "Study of Biomarker-Based Treatment of Acute Myeloid Leukemia", "overall_status": "RECRUITING", "study_type": "INTERVENTIONAL", "phases": [ "PHASE2", "PHASE3" ], "conditions": [ "Previously Untreated Relapsed Refractory Acute Myeloid Leukemia" ], "interventions": [ { "name": "Samalizumab (BAML-16-001-S1)", "type": "BIOLOGICAL" }, { "name": "BI 836858 (BAML-16-001-S2)", "type": "BIOLOGICAL" }, { "name": "Laboratory Biomarker Analysis", "type": "OTHER" }, { "name": "Daunorubicin (BAML-16-001-S1)", "type": "DRUG" }, { "name": "Cytarabine (BAML-16-001-S1)", "type": "DRUG" }, { "name": "Azacitidine (BAML-16-001-S2)", "type": "DRUG" }, { "name": "AG-221 (BAML-16-001-S3)", "type": "DRUG" }, { "name": "Azacitidine (BAML-16-001-S3)", "type": "DRUG" }, { "name": "Entospletinib (BAML-16-001-S4)", "type": "DRUG" }, { "name": "Azacitidine (BAML-16-001-S4)", "type": "DRUG" }, { "name": "Entospletinib (BAML-16-001-S5)", "type": "DRUG" }, { "name": "Decitabine (BAML-16-001-S5)", "type": "DRUG" }, { "name": "Entospletinib (BAML-16-001-S6)", "type": "DRUG" }, { "name": "Daunorubicin (BAML-16-001-S6)", "type": "DRUG" }, { "name": "Cytarabine (BAML-16-001-S6)", "type": "DRUG" }, { "name": "Pevonedistat (BAML-16-001-S9)", "type": "DRUG" }, { "name": "Azacitidine (BAML-16-001-S9)", "type": "DRUG" }, { "name": "AG-120 (BAML-16-001-S16)", "type": "DRUG" }, { "name": "Azacitidine (BAML-16-001-S16)", "type": "DRUG" }, { "name": "Gilteritinib (BAML-16-001-S8 Group 1)", "type": "DRUG" }, { "name": "Decitabine (BAML-16-001-S8 Group 1)", "type": "DRUG" }, { "name": "AZD5153 (BAML-16-001-S10)", "type": "DRUG" }, { "name": "Venetoclax (BAML-16-001-S10)", "type": "DRUG" }, { "name": "TP-0903 (BAML-16-001-S14)", "type": "DRUG" }, { "name": "Decitabine (BAML-16-001-S14)", "type": "DRUG" }, { "name": "Decitabine (BAML-16-001-S8 Group 2)", "type": "DRUG" }, { "name": "Venetoclax (BAML-16-001-S8 Group 2)", "type": "DRUG" }, { "name": "AZD5991 (BAML-16-001-S18)", "type": "DRUG" }, { "name": "Azacitidine (BAML-16-001-S18)", "type": "DRUG" }, { "name": "SNDX-5613 (BAML-16-001-S17)", "type": "DRUG" }, { "name": "Azacitidine (BAML-16-001-S17)", "type": "DRUG" }, { "name": "Venetoclax (BAML-16-001-S17)", "type": "DRUG" }, { "name": "Gilteritinib (BAML-16-001-S8 Group 2)", "type": "DRUG" }, { "name": "Venetoclax (BAML-16-001-S12 Arm A)", "type": "DRUG" }, { "name": "Azacitidine (BAML-16-001-S12 Arm A)", "type": "DRUG" }, { "name": "Venetoclax (BAML-16-001-S12 Arm B)", "type": "DRUG" }, { "name": "Azacitidine (BAML-16-001-S12 Arm B)", "type": "DRUG" }, { "name": "ZE46-0134 (BAML-16-001-S21 Group 1)", "type": "DRUG" }, { "name": "ficlatuzumab (BAML-16-001-S24)", "type": "DRUG" }, { "name": "Azacitidine (BAML-16-001-S24)", "type": "DRUG" }, { "name": "Venetoclax (BAML-16-001-S24)", "type": "DRUG" }, { "name": "ZE46-0134 (BAML-16-001-S21 Group 2)", "type": "DRUG" }, { "name": "Bleximenib (BAML-16-001-S25/HO181)", "type": "DRUG" }, { "name": "Cytarabine (BAML-16-001-S25/HO181)", "type": "DRUG" }, { "name": "Daunorubicin or Idarubicin (BAML-16-001-S25/HO181)", "type": "DRUG" }, { "name": "Placebo (BAML-16-001-S25/HO181)", "type": "DRUG" }, { "name": "Revumenib (BAML-16-001-S26/HO177)", "type": "DRUG" }, { "name": "Placebo (BAML-16-001-S26/HO177)", "type": "DRUG" } ], "intervention_types": [ "BIOLOGICAL", "OTHER", "DRUG" ], "sponsor": "Beat AML, LLC", "sponsor_class": "OTHER", "healthy_volunteers": false, "eligibility": { "minimum_age": "18 Years", "maximum_age": null, "sex": "ALL", "summary": "18 Years and older" }, "enrollment_count": 3000, "start_date": "2016-11", "completion_date": "2032-12", "has_results": false, "last_update_posted_date": "2026-09-03", "last_synced_at": "2026-09-26T11:54:21.516Z", "location_count": 31, "location_summary": "Phoenix, Arizona • Scottsdale, Arizona • Los Angeles, California + 26 more", "locations": [ { "city": "Phoenix", "state": "Arizona" }, { "city": "Scottsdale", "state": "Arizona" }, { "city": "Los Angeles", "state": "California" }, { "city": "San Francisco", "state": "California" }, { "city": "Denver", "state": "Colorado" } ], "official_url": "https://clinicaltrials.gov/study/NCT03013998" }, { "nct_id": "NCT04289363", "title": "Emergency Department Outcomes for Patients With Opioid Use Disorder", "overall_status": "COMPLETED", "study_type": "OBSERVATIONAL", "phases": [], "conditions": [ "Opioid-use Disorder" ], "interventions": [ { "name": "Clinical program implementation", "type": "BEHAVIORAL" } ], "intervention_types": [ "BEHAVIORAL" ], "sponsor": "NYU Langone Health", "sponsor_class": "OTHER", "healthy_volunteers": false, "eligibility": { "minimum_age": "18 Years", "maximum_age": null, "sex": "ALL", "summary": "18 Years and older" }, "enrollment_count": 53, "start_date": "2020-11-25", "completion_date": "2022-02-18", "has_results": true, "last_update_posted_date": "2023-07-06", "last_synced_at": "2026-09-26T11:54:21.516Z", "location_count": 2, "location_summary": "Manchester, New Hampshire • New York, New York", "locations": [ { "city": "Manchester", "state": "New Hampshire" }, { "city": "New York", "state": "New York" } ], "official_url": "https://clinicaltrials.gov/study/NCT04289363" }, { "nct_id": "NCT06116435", "title": "A Pilot Factorial Trial of an Integrated Lifestyle Intervention", "overall_status": "RECRUITING", "study_type": "INTERVENTIONAL", "phases": [ "NA" ], "conditions": [ "Physical Inactivity", "Overweight and Obesity" ], "interventions": [ { "name": "Prevent T2", "type": "BEHAVIORAL" }, { "name": "Move group-based classes", "type": "BEHAVIORAL" }, { "name": "Fitness Membership", "type": "BEHAVIORAL" }, { "name": "Mental Imagery", "type": "BEHAVIORAL" }, { "name": "Move 1:1 Support", "type": "BEHAVIORAL" } ], "intervention_types": [ "BEHAVIORAL" ], "sponsor": "University of Colorado, Denver", "sponsor_class": "OTHER", "healthy_volunteers": true, "eligibility": { "minimum_age": "18 Years", "maximum_age": "65 Years", "sex": "ALL", "summary": "18 Years to 65 Years" }, "enrollment_count": 64, "start_date": "2023-12-04", "completion_date": "2027-03", "has_results": false, "last_update_posted_date": "2024-05-14", "last_synced_at": "2026-09-26T11:54:21.516Z", "location_count": 1, "location_summary": "Aurora, Colorado", "locations": [ { "city": "Aurora", "state": "Colorado" } ], "official_url": "https://clinicaltrials.gov/study/NCT06116435" }, { "nct_id": "NCT04053335", "title": "Smarter Care Virginia, Examining Low-Value Care in Virginia", "overall_status": "COMPLETED", "study_type": "OBSERVATIONAL", "phases": [], "conditions": [ "Chronic Kidney Diseases", "Eye Diseases", "Cardiac Disease", "Surgery", "Low Back Pain" ], "interventions": [ { "name": "Multicomponent Physician Performance Peer-Comparison Feedback Intervention", "type": "BEHAVIORAL" } ], "intervention_types": [ "BEHAVIORAL" ], "sponsor": "University of California, Los Angeles", "sponsor_class": "OTHER", "healthy_volunteers": false, "eligibility": { "minimum_age": "18 Years", "maximum_age": null, "sex": "ALL", "summary": "18 Years and older" }, "enrollment_count": 5000000, "start_date": "2019-07-25", "completion_date": "2022-12-31", "has_results": false, "last_update_posted_date": "2023-07-03", "last_synced_at": "2026-09-26T11:54:21.516Z", "location_count": 1, "location_summary": "Los Angeles, California", "locations": [ { "city": "Los Angeles", "state": "California" } ], "official_url": "https://clinicaltrials.gov/study/NCT04053335" }, { "nct_id": "NCT01816841", "title": "Direct Visual Fluorescence in Finding Oral Cancer in High-Risk Patients and Patients Undergoing Routine Dental Care", "overall_status": "COMPLETED", "study_type": "INTERVENTIONAL", "phases": [ "NA" ], "conditions": [ "Lip and Oral Cavity Squamous Cell Carcinoma", "Oral Cavity Verrucous Carcinoma", "Stage 0 Lip and Oral Cavity Cancer", "Tongue Cancer" ], "interventions": [ { "name": "fluorescence imaging", "type": "PROCEDURE" }, { "name": "biopsy", "type": "PROCEDURE" }, { "name": "examination", "type": "PROCEDURE" }, { "name": "Comparison of surgical margins by COE vs. DVFE", "type": "PROCEDURE" } ], "intervention_types": [ "PROCEDURE" ], "sponsor": "Ohio State University Comprehensive Cancer Center", "sponsor_class": "OTHER", "healthy_volunteers": false, "eligibility": { "minimum_age": "18 Years", "maximum_age": null, "sex": "ALL", "summary": "18 Years and older" }, "enrollment_count": 68, "start_date": "2008-11-11", "completion_date": "2019-12-28", "has_results": false, "last_update_posted_date": "2020-01-30", "last_synced_at": "2026-09-26T11:54:21.516Z", "location_count": 1, "location_summary": "Columbus, Ohio", "locations": [ { "city": "Columbus", "state": "Ohio" } ], "official_url": "https://clinicaltrials.gov/study/NCT01816841" }, { "nct_id": "NCT06443866", "title": "I-124 PET/CT Imaging and Dosimetry for RAI-Naïve or Refractory Thyroid Cancer", "overall_status": "RECRUITING", "study_type": "OBSERVATIONAL", "phases": [], "conditions": [ "Thyroid Cancer", "RAI-Refractory Thyroid Cancer" ], "interventions": [ { "name": "Disease status detection", "type": "DIAGNOSTIC_TEST" }, { "name": "Theranostic dosimetry", "type": "DIAGNOSTIC_TEST" }, { "name": "I-124 PET/CT imaging", "type": "DRUG" } ], "intervention_types": [ "DIAGNOSTIC_TEST", "DRUG" ], "sponsor": "Miami Cancer Research Center, Inc.", "sponsor_class": "OTHER", "healthy_volunteers": false, "eligibility": { "minimum_age": "18 Years", "maximum_age": null, "sex": "ALL", "summary": "18 Years and older" }, "enrollment_count": 50, "start_date": "2022-02-01", "completion_date": "2029-12", "has_results": false, "last_update_posted_date": "2024-06-05", "last_synced_at": "2026-09-26T11:54:21.516Z", "location_count": 1, "location_summary": "North Miami, Florida", "locations": [ { "city": "North Miami", "state": "Florida" } ], "official_url": "https://clinicaltrials.gov/study/NCT06443866" }, { "nct_id": "NCT04179162", "title": "Bacillus Calmette-Guérin (BCG) and Gemcitabine in People With High-Grade Non-Muscle Invasive Bladder Cancer That Came Back After BCG Treatment", "overall_status": "ACTIVE_NOT_RECRUITING", "study_type": "INTERVENTIONAL", "phases": [ "PHASE1", "PHASE2" ], "conditions": [ "Non-Muscle Invasive Bladder Cancer (NMIBC)" ], "interventions": [ { "name": "Bacillus Calmette-Guérin (BCG)", "type": "DRUG" }, { "name": "Gemcitabine", "type": "DRUG" } ], "intervention_types": [ "DRUG" ], "sponsor": "Memorial Sloan Kettering Cancer Center", "sponsor_class": "OTHER", "healthy_volunteers": false, "eligibility": { "minimum_age": "18 Years", "maximum_age": null, "sex": "ALL", "summary": "18 Years and older" }, "enrollment_count": 54, "start_date": "2019-11-22", "completion_date": "2027-11", "has_results": false, "last_update_posted_date": "2026-08-11", "last_synced_at": "2026-09-26T11:54:21.516Z", "location_count": 8, "location_summary": "Hartford, Connecticut • Basking Ridge, New Jersey • Middletown, New Jersey + 5 more", "locations": [ { "city": "Hartford", "state": "Connecticut" }, { "city": "Basking Ridge", "state": "New Jersey" }, { "city": "Middletown", "state": "New Jersey" }, { "city": "Montvale", "state": "New Jersey" }, { "city": "Commack", "state": "New York" } ], "official_url": "https://clinicaltrials.gov/study/NCT04179162" }, { "nct_id": "NCT03191058", "title": "Confirmatory Efficacy and Safety Trial of Magnetic Seizure Therapy for Depression", "overall_status": "COMPLETED", "study_type": "INTERVENTIONAL", "phases": [ "NA" ], "conditions": [ "Depression", "Unipolar Depression", "Treatment Resistant Depression" ], "interventions": [ { "name": "Magnetic Seizure Therapy", "type": "DEVICE" }, { "name": "Electroconvulsive Therapy", "type": "DEVICE" } ], "intervention_types": [ "DEVICE" ], "sponsor": "University of Texas Southwestern Medical Center", "sponsor_class": "OTHER", "healthy_volunteers": false, "eligibility": { "minimum_age": "18 Years", "maximum_age": null, "sex": "ALL", "summary": "18 Years and older" }, "enrollment_count": 239, "start_date": "2018-06-26", "completion_date": "2024-11-22", "has_results": true, "last_update_posted_date": "2026-05-11", "last_synced_at": "2026-09-26T11:54:21.516Z", "location_count": 2, "location_summary": "San Diego, California • Dallas, Texas", "locations": [ { "city": "San Diego", "state": "California" }, { "city": "Dallas", "state": "Texas" } ], "official_url": "https://clinicaltrials.gov/study/NCT03191058" } ] }